Nexentis Technologies Inc. reports company developments tied to mitochondrial drug discovery, solar energy asset investments, and its controlled interest in Save Foods Ltd. News about the company includes updates from MitoCareX Bio Ltd., including the MITOLINE™ algorithm platform for SLC25 mitochondrial carrier protein analysis and 3D homology modeling.
Recurring Nexentis news also covers public-company capital actions, Nasdaq trading matters, and the company’s mix of biotechnology, Ready to Build solar assets, and post-harvest treatment technology exposure through Save Foods.
Nexentis Technologies (NXTS) approved a 1-for-5 reverse stock split scheduled to take effect for Nasdaq purposes on November 9, 2026.
Split-adjusted trading will begin that day on the Nasdaq Capital Market under the unchanged symbol NXTS. Every five outstanding common shares will become one share, reducing outstanding shares from approximately 2.9 million to approximately 600 thousand. Authorized common shares will remain unchanged. The company gives regaining compliance with Nasdaq’s continued listing requirements and attracting certain institutional investors as reasons for the reverse split authorization.
Nexentis Technologies (NXTS) announced that subsidiary MitoCareX Bio completed an initial computational screening stage in its drug-discovery initiative with Boltz.
The initiative, announced in June 2026, combines MitoCareX’s discovery capabilities with Boltz’s AI models to identify potential small-molecule starting points. MitoCareX considers the preliminary predictions encouraging enough for further analysis and experimental investigation, but they have not been experimentally validated. Further scientific assessment and validation will determine whether any program advances. MitoCareX retains control over its discovery programs and any small-molecule candidates it advances through the initiative.
Nexentis Technologies (NXTS) announced that subsidiary MitoCareX Bio completed the initial computational screening stage of its drug-discovery initiative with Boltz. The initiative, launched in June 2026, uses Boltz’s AI models alongside MitoCareX’s discovery capabilities to identify potential small-molecule starting points for selected programs.
MitoCareX considers the preliminary predictions encouraging enough for further computational analysis and experimental validation. The findings have not been experimentally validated; further scientific assessment will determine whether they support advancing any program. MitoCareX retains control over its discovery programs and any candidates it advances through the initiative.
Nexentis Technologies (NASDAQ: NXTS) announced that its wholly owned subsidiary MitoCareX Bio is expanding bioinformatics expertise within its computational drug-discovery platform. MitoCareX has added an expert bioinformatician and is developing a greater focus on disease-relevant biological pathways, the linked processes involved in disease.
Preliminary analyses are informing continued platform development. MitoCareX plans to integrate the developing capabilities with its existing structural and molecular research. It intends to use disease-related context to assess potential targets and research programs before they enter resource-intensive discovery activities.
Nexentis Technologies (NASDAQ: NXTS) announced that its wholly owned subsidiary, MitoCareX Bio, now deploys its computational drug discovery infrastructure on Google Cloud Platform. The transition supports the subsidiary's computing activities and evolving drug discovery requirements.
The company expects the environment to align computing capacity with program needs, centralize scientific data management and apply consistent user permissions. Computing and storage resources are intended to adapt to changing project requirements. The framework is also expected to support existing research programs and the evaluation of additional discovery opportunities as priorities change.
Nexentis (NXTS) announced on September 24, 2026, that Prof. Dan T. Major joined the scientific advisory board of its subsidiary MitoCareX. Major will advise on the evaluation and application of computational chemistry and computer-based drug-discovery methods. He is a chemistry professor at Bar-Ilan University whose research includes molecular simulations and computational drug development.
Nexentis said the appointment supports MitoCareX’s efforts to expand internal computational capabilities for assessing and prioritizing discovery programs. MitoCareX previously began a drug-discovery collaboration with Boltz, an AI research lab focused on biomolecular foundation models and drug-discovery workflows.
Nexentis (NXTS) reported that its wholly owned subsidiary, MitoCareX Bio, is evaluating additional established, commercially available approaches for obtaining proteins used in its in-vitro research activities.
The assessment aims to broaden available research tools, enhance access to protein materials and support flexibility as MitoCareX’s future drug discovery programs progress. The company described this process as part of a disciplined, methodical effort to develop reliable in-vitro research capabilities. The evaluation is at an early stage, and there is no assurance that any of the approaches under review will be adopted or provide anticipated benefits.
Nexentis Technologies (NASDAQ: NXTS) announced that its wholly owned subsidiary MitoCareX Bio has selected a prioritized SLC transport protein candidate for a new drug discovery campaign, following a broad structural analysis of the human SLC transport protein family using its proprietary MITOLINE® platform.
According to Nexentis, the candidate arises from a set of non‑mitochondrial SLC transport proteins previously identified as compatible with MITOLINE®-enabled structural modelling. MitoCareX completed an internal prioritization process and chose a target with favorable characteristics, which the company views as a concrete step in translating its computational discovery capabilities into a focused pipeline.
Nexentis Technologies (NASDAQ:NXTS) announced that subsidiary MitoCareX Bio completed a broad analysis of SLC transport proteins using its proprietary MITOLINE® algorithm and entered an international AI-driven small-molecule discovery initiative with Boltz.
The work targets hard-to-treat cancers and inflammatory metabolic diseases and aims to expand SLC-focused small-molecule discovery programs.
Nexentis (NASDAQ:NXTS) signed an addendum with Solterra and other lenders for the Melz solar PV project in Germany, monetizing part of its investment at a $14.5 million project valuation ($120,000 per MW), which Nexentis describes as a significant premium to its initial investment.
Nexentis will receive about $147,000 in early loan repayment, $98,000 from selling 10% of its profit rights (2.5% of project profits), and a $22,000 option fee, while retaining remaining profit rights and an RTB-based exit option. The lender group committed approximately $2.95 million, including $2.18 million from Nexentis, to advance the ~115 MWp Melz project to Ready-to-Build stage.